Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone marrow transplantation

T S Vats1

  • 1University of Kansas Medical Center, Kansas City 66160-7357.

Indian Journal of Pediatrics
|July 1, 1993
PubMed
Summary
This summary is machine-generated.

Bone marrow transplantation (BMT) offers superior survival for acute myeloid leukemia and CML with HLA-identical donors. For recurrent lymphomas, BMT in remission yields best results, while mismatched donor transplants remain experimental.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric non-Hodgkin lymphomas in children: diagnosis and current management.

Indian pediatrics·2001
Same author

Malignancies in Down syndrome.

Indian journal of pediatrics·2000
Same author

Adjuvant chemotherapy of pediatric brain tumors.

Annals of the New York Academy of Sciences·1997
Same author

Psychosocial adjustment and the role of functional status for children with asthma.

The Journal of asthma : official journal of the Association for the Care of Asthma·1995
Same author

Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children.

Infection·1993
Same author

Oncogenes: present status.

Indian journal of pediatrics·1993
Same journal

Bilateral Parotid Enlargement as an Initial Manifestation of Pediatric Acute Lymphoblastic Leukemia.

Indian journal of pediatrics·2026
Same journal

Hemorrhagic Cardiac Tamponade Due to MRSA Sepsis in a Child with Relapsed Acute Lymphoblastic Leukemia: Authors' Reply.

Indian journal of pediatrics·2026
Same journal

A Prospective Model for Detecting Missed Appendicitis in Low-Risk Pediatric Patients: Correspondence.

Indian journal of pediatrics·2026
Same journal

Serum Periostin as a Biomarker in Pediatric Asthma: Findings from a Case-Control Study - Authors' Reply.

Indian journal of pediatrics·2026
Same journal

When the Eye Peels: An Unusual Harbinger of Kawasaki Disease - Correspondence.

Indian journal of pediatrics·2026
Same journal

Pediatric Sleep-Related Laryngospasm: Cause of Nocturnal Respiratory Distress.

Indian journal of pediatrics·2026
See all related articles

Area of Science:

  • Hematology
  • Oncology
  • Transplantation Medicine

Background:

  • Bone marrow transplantation (BMT) is a critical treatment for leukemias and lymphomas.
  • Allogeneic transplants with HLA-identical donors significantly improve survival in acute myeloid leukemia and chronic myeloid leukemia compared to chemotherapy.

Purpose of the Study:

  • To evaluate the efficacy of bone marrow transplantation in treating leukemias and lymphomas.
  • To define optimal patient selection and timing for BMT in hematologic malignancies.

Main Methods:

  • Review of outcomes for allogeneic bone marrow transplantation in patients with leukemia and lymphoma.
  • Analysis of survival data based on donor type (HLA-identical, mismatched family, unrelated) and disease remission status.

Related Experiment Videos

Main Results:

  • Allogeneic BMT with HLA-identical donors provides superior survival for acute myeloid leukemia and CML patients compared to chemotherapy.
  • Transplantation in first remission for Ph' chromosome-positive CML and in complete remission for recurrent lymphomas yields optimal results.
  • Transplants using minor mismatched family or unrelated donors are experimental and require further investigation.

Conclusions:

  • BMT is a highly effective treatment for selected leukemias and lymphomas, potentially offering the only viable option.
  • Careful patient selection, consideration of donor type, and robust supportive services are essential for successful BMT programs.
  • Further research is needed to establish the role of mismatched donor transplants in hematologic malignancies.